Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $32.80 Average PT from Brokerages

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) have earned a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $32.80.

GLUE has been the topic of a number of recent research reports. Zacks Research cut shares of Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 4th. Weiss Ratings reissued a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research report on Monday, December 29th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $31.00 target price on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Wedbush reiterated an “outperform” rating and set a $37.00 target price on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th. Finally, Wells Fargo & Company lowered their price target on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, March 18th.

Insider Activity at Monte Rosa Therapeutics

In other news, CEO Markus Warmuth sold 5,466 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $17.92, for a total transaction of $97,950.72. Following the completion of the sale, the chief executive officer owned 613,471 shares in the company, valued at $10,993,400.32. This represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Edmund Dunn sold 25,164 shares of the stock in a transaction on Friday, February 27th. The stock was sold at an average price of $18.10, for a total value of $455,468.40. Following the sale, the insider directly owned 22,693 shares of the company’s stock, valued at approximately $410,743.30. This represents a 52.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 36,771 shares of company stock worth $693,692 over the last quarter. Company insiders own 6.50% of the company’s stock.

Institutional Trading of Monte Rosa Therapeutics

Several hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC purchased a new position in Monte Rosa Therapeutics during the first quarter worth about $1,065,000. Goldman Sachs Group Inc. raised its stake in shares of Monte Rosa Therapeutics by 122.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 356,112 shares of the company’s stock worth $1,652,000 after buying an additional 196,238 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Monte Rosa Therapeutics in the 1st quarter valued at approximately $76,000. Geode Capital Management LLC lifted its holdings in shares of Monte Rosa Therapeutics by 12.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,124,160 shares of the company’s stock valued at $5,071,000 after buying an additional 120,098 shares during the period. Finally, Intech Investment Management LLC boosted its stake in shares of Monte Rosa Therapeutics by 35.4% in the second quarter. Intech Investment Management LLC now owns 29,870 shares of the company’s stock valued at $135,000 after buying an additional 7,808 shares in the last quarter. Institutional investors and hedge funds own 79.96% of the company’s stock.

Monte Rosa Therapeutics Stock Up 5.9%

Shares of NASDAQ GLUE opened at $16.45 on Friday. The business has a 50-day moving average price of $18.44 and a 200 day moving average price of $15.50. The stock has a market cap of $1.32 billion, a PE ratio of -35.76 and a beta of 1.63. Monte Rosa Therapeutics has a 52-week low of $3.50 and a 52-week high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings results on Tuesday, March 17th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.10). The firm had revenue of $2.78 million for the quarter, compared to analyst estimates of $17.09 million. Monte Rosa Therapeutics had a negative return on equity of 15.12% and a negative net margin of 31.23%. Sell-side analysts anticipate that Monte Rosa Therapeutics will post -1.49 earnings per share for the current year.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.